Brolucizumab ÁÖ»çÁ¦(Ç°¸í: ºñ¿ÀºäÇÁ¸®Çʵå½Ã¸°Áö) ¡á °í½Ã ½Å¼³ Àüü³»¿ë Çã°¡»çÇ× ¹üÀ§ ³»¿¡¼ ¾Æ·¡¿Í °°Àº ±âÁØÀ¸·Î Åõ¿© ½Ã ¿ä¾ç±Þ¿©¸¦ ÀÎÁ¤Çϸç, µ¿ ÀÎÁ¤±âÁØ ÀÌ¿Ü¿¡´Â ¾à°ª Àü¾×À» ȯÀÚ°¡ ºÎ´ãÅä·Ï ÇÔ. - ¾Æ ·¡ - ¡Û ½Å»ýÇ÷°ü¼º(½À¼º) ¿¬·É°ü·Ã Ȳ¹Ýº¯¼º °¡. Åõ¿©´ë»ó: ¿¬·É°ü·Ã Ȳ¹Ýº¯¼º(Age-related macular degeneration)¿¡ ÀÇÇÑ È²¹ÝÇÏ ¸Æ¶ô¸· ½Å»ýÇ÷°ü(Subfoveal choroidal neovascularization)À» °¡Áø ȯÀÚ. ´Ù¸¸, ¹ÝÈçÈµÈ °æ¿ì³ª À§ÃàÀÌ ½ÉÇÑ °æ¿ì µîÀº Åõ¿© ´ë»ó¿¡¼ Á¦¿ÜÇÔ. ³ª. Åõ¿©¹æ¹ý 1) Ãʱâ 3ȸ Åõ¿© ÈÄ¿¡µµ Ä¡·áÈ¿°ú°¡ º¸ÀÌÁö ¾ÊÀ¸¸é ±× ÀÌÈÄ Åõ¿©´Â ±Þ¿©·Î ÀÎÁ¤ÇÏÁö ¾Æ´ÏÇÔ. 2) Aflibercept ¶Ç´Â Ranibizumab ÁÖ»çÁ¦¿¡¼ µ¿ ¾àÁ¦·Î ±³Ã¼(Åõ¿©¼Ò°ß¼ ÷ºÎ)ÇÏ¿© 3ȸ Åõ¿© ÈÄ¿¡µµ Ä¡·áÈ¿°ú°¡ º¸ÀÌÁö ¾ÊÀ¸¸é ±× ÀÌÈÄ Åõ¿©´Â ±Þ¿©·Î ÀÎÁ¤ÇÏÁö ¾Æ´ÏÇÔ. 3) 5ȸ Åõ¿©ºÎÅÍ´Â ±³Á¤½Ã·ÂÀÌ 0.1ÀÌÇÏÀÎ °æ¿ì ±Þ¿©·Î ÀÎÁ¤ÇÏÁö ¾Æ´ÏÇÔ.(´Ü¾È½ÃÀÇ °æ¿ì »ç·Êº°·Î ÀÎÁ¤) ´Ù. Verteporfin(Ç°¸í: ºñÁê´ÙÀÎ)°úÀÇ º´¿ëÅõ¿©´Â ±Þ¿©·Î ÀÎÁ¤ÇÏÁö ¾Æ´ÏÇÔ. ¡á °í½Ã ½Å¼³ °í½Ã¹øÈ£(½ÃÇàÀÏÀÚ) °í½Ã Á¦2021-101È£(2021.4.1.) ¡á °í½Ã ½Å¼³ »çÀ¯ Brolucizumab ÁÖ»çÁ¦°¡ µîÀç ¿¹Á¤ÀÓ¿¡ µû¶ó, ±³°ú¼, °¡À̵å¶óÀÎ, ÀÓ»ó³í¹®, ÇÐȸÀÇ°ß, Á¦¿Ü±¹ Æò°¡°á°ú, °ü·Ã ±Þ¿©±âÁØ µîÀ» ÂüÁ¶ÇÏ¿© ±Þ¿©±âÁØÀ» ½Å¼³ÇÔ ¡á °ü·Ã¹®Çå µî ¡¤ Kanski's Clinical Ophthalmology, 9th. 2020. ¡¤ Massachusetts Eye and Ear Infirmary Illustrated Manual of Ophthalmology, 5th. 2021. ¡¤ American Academy of Ophthalmology guideline: Age-Related Macular Degeneration Preferred Practice Pattern. 2019. ¡¤ Dugel et al. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020 Jan;127(1):72-84. ¡¤ Dugel et al. HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020 Jun 20; S0161-6420(20)30570-4. ¡¤ Dugel et al. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial. Ophthalmology. 2017 Sep;124(9):1296-1304. ¡¤ SMC(2020.8.) ¡¤ CADTH(2020.5.) ¡¤ PBAC(2019.11.) Ãâó : °Ç°º¸Çè½É»çÆò°¡¿ø |